SCHEMBL1744689

SCHEMBL1744689

COC(=O)CCc1ccc(OC2CCc3cc(OCCc4ccccc4)ccc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 2/20 0.46
▸ KDM4C Q9H3R0 2/20 0.45
▸ PPARD Q03181 5/20 0.44
▸ PPARA Q07869 6/20 0.44
▸ PPARG P37231 7/20 0.43
▸ GFRA3 O60609 1/20 0.43
▸ RET P07949 1/20 0.43
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ LTA4H P09960 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745404 0.94 FFAR1 (0.47) FFAR1PPARDPPARAPPARG
SCHEMBL1744612 0.92 FFAR1 (0.48) FFAR1
SCHEMBL1746827 0.90 FFAR1 (0.58) FFAR1KDM4CPPARDPPARAPPARG
SCHEMBL1744736 0.88 FFAR1 (0.44) FFAR1PPARDGFRA3RET
SCHEMBL1747248 0.87 GRIN2B (0.44) FFAR1PPARD
SCHEMBL1745440 0.86 GFRA3 (0.48) FFAR1PPARDGFRA3RET
SCHEMBL1745539 0.86 FFAR1 (0.40) FFAR1PPARDPPARA
SCHEMBL1746434 0.85 RXRA (0.47) FFAR1MAOAMAOBLTA4H
SCHEMBL1744692 0.84 FFAR1 (0.52) FFAR1GFRA3
SCHEMBL1745225 0.84 FFAR1 (0.52) FFAR1GFRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 — — EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 — — EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 — — EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 — — US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 — — US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 — — US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 — — US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 — — US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 — — US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885KDM4C 4428/4885PPARD 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback